CRIS Current Research Information System

GRAMANTIERI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.001
AS - Asia 2.593
EU - Europa 2.309
AF - Africa 172
SA - Sud America 147
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 1
Totale 8.239
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.966
SG - Singapore 949
CN - Cina 858
IT - Italia 604
GB - Regno Unito 396
DE - Germania 261
SE - Svezia 253
HK - Hong Kong 202
VN - Vietnam 175
NL - Olanda 142
IN - India 140
KR - Corea 118
RU - Federazione Russa 115
BR - Brasile 101
FR - Francia 97
IE - Irlanda 96
CH - Svizzera 79
UA - Ucraina 59
FI - Finlandia 46
BG - Bulgaria 41
CI - Costa d'Avorio 41
TG - Togo 40
JP - Giappone 38
ZA - Sudafrica 37
ID - Indonesia 35
SC - Seychelles 32
EE - Estonia 28
CA - Canada 24
EC - Ecuador 21
JO - Giordania 21
AT - Austria 15
EU - Europa 15
PL - Polonia 15
PK - Pakistan 14
BE - Belgio 11
AR - Argentina 10
HR - Croazia 10
MK - Macedonia 9
MX - Messico 8
BD - Bangladesh 7
DZ - Algeria 7
NG - Nigeria 6
PE - Perù 6
RO - Romania 6
ES - Italia 5
IL - Israele 5
LT - Lituania 5
MY - Malesia 5
TR - Turchia 5
AM - Armenia 4
CZ - Repubblica Ceca 4
UZ - Uzbekistan 4
GR - Grecia 3
LB - Libano 3
PY - Paraguay 3
CL - Cile 2
DK - Danimarca 2
IR - Iran 2
KZ - Kazakistan 2
MD - Moldavia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
CU - Cuba 1
EG - Egitto 1
HN - Honduras 1
IQ - Iraq 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MA - Marocco 1
ML - Mali 1
MR - Mauritania 1
NC - Nuova Caledonia 1
TH - Thailandia 1
UY - Uruguay 1
Totale 8.239
Salva come PNG Salva come JPEG
Città #
Singapore 651
Ashburn 404
Southend 349
Fairfield 302
Hefei 271
Chandler 214
Bologna 205
Hong Kong 201
Woodbridge 159
Santa Clara 155
Houston 145
Wilmington 131
Seattle 129
Seoul 118
Beijing 115
Boardman 98
Dublin 96
Princeton 88
Ann Arbor 79
Cambridge 79
Bern 75
Dallas 73
Los Angeles 44
Milan 42
Abidjan 41
Sofia 41
Lomé 40
New York 39
Ho Chi Minh City 36
Dong Ket 35
Jacksonville 34
Westminster 34
Nanjing 32
Padova 32
Tokyo 32
Hanoi 31
Helsinki 30
Redondo Beach 28
Buffalo 25
Munich 25
Amsterdam 24
Bengaluru 24
Berlin 23
Jakarta 22
Amman 21
Florence 19
Saint Petersburg 19
Jinan 18
Zhengzhou 18
Chicago 17
Hebei 17
San Diego 17
Turin 16
Düsseldorf 14
Frankfurt am Main 14
São Paulo 14
Brussels 11
Nanchang 11
Nuremberg 11
Shanghai 11
Brooklyn 10
Da Nang 10
Des Moines 10
Jiaxing 10
Orem 10
Phoenix 10
Pune 10
Quito 10
Shenyang 10
Bremen 9
Changsha 9
Guangzhou 9
Lahore 9
Medford 9
Rome 9
Tongling 9
Verona 9
Vienna 9
Bühl 8
Dearborn 8
Falls Church 8
Forlì 8
Haikou 8
Lappeenranta 8
Lauterbourg 8
London 8
Mülheim 8
Norwalk 8
Toronto 8
Warsaw 8
Council Bluffs 7
Denver 7
Falkenstein 7
Guayaquil 7
Montreal 7
Turku 7
Yubileyny 7
Abeokuta 6
Chennai 6
Ferrara 6
Totale 5.433
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 240
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 221
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 197
LncRNAs as novel players in hepatocellular carcinoma recurrence 193
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 191
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 180
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 177
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 176
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 173
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 171
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 167
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 162
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 160
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 159
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 155
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 154
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 154
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 153
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 150
Oncogenic role of miR-483-3p at the IGF2/483 locus. 148
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 148
Targeting notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives 143
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 142
Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. 142
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 141
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. 141
GADD45alpha expression in cirrhosis and hepatocellular carcinoma. Relationship with DNA-repair and proliferation. 140
Improving accuracy in the diagnosis of small HCC (< 20 mm) on cirrhosis by a combined CT-MRI Ultrasound navigation system. Preliminary report of a work in progress. 140
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 139
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 138
TP53/MicroRNA interplay in hepatocellular carcinoma 137
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 136
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 136
Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas 135
MicroRNAs in Animal Models of HCC 126
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 125
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 123
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 121
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 120
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 120
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies 119
T.N.28 P53 IS REGULATED BY NOTCH3 SIGNALLING VIA MDM2 IN HEPATOCELLULAR CARCINOMA 116
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 114
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. 113
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches 112
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 112
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 111
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC 105
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 104
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 102
Efficacy of superselective TACE in treatment of HCC 100
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma 99
Notch3 intracellular domain accumulates in HepG2 cell line. 97
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 94
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 85
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 80
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 78
null 77
Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells 74
Emerging role of microRNAs in the treatment of hepatocellular carcinoma 67
miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature 66
Animal models of hepatocellular carcinoma prevention 62
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 53
Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver 44
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated HCC patients. 22
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 19
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 16
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 16
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 9
Mir-30e-3p/CXCL3 axis is involved in sorafenib resistance of hepatocellular carcinoma through the modulation of the tumor immune microenvironment 7
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 6
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 5
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 4
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 3
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 3
Totale 8.468
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.467
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.467
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021365 0 0 0 0 0 38 43 40 75 47 24 98
2021/2022976 55 44 60 86 74 47 19 96 36 84 253 122
2022/20231.084 99 121 62 123 65 93 21 57 192 28 76 147
2023/2024411 32 70 19 37 55 79 13 20 19 30 13 24
2024/20251.731 87 222 141 116 214 55 121 45 44 181 133 372
2025/20262.316 421 427 400 322 455 291 0 0 0 0 0 0
Totale 8.468